Pharma BD Deal Intelligence
A textbook China in-license: AstraZeneca paid just $55M upfront (up to $600M total) for LaNova's preclinical GPRC5D ADC LM-305, renamed it AZD0305, and had it into an AstraZeneca-sponsored Phase I/II myeloma trial with ASH 2024 data — though the milestone-heavy structure means most of the value is still unrealized.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →AstraZeneca has entered into an exclusive global license agreement with LaNova Medicines for LM-305, a potentially first-in-class antibody-drug conjugate…
AstraZeneca has licensed a preclinical GPRC5D-targeting antibody-drug conjugate from Shanghai-based LaNova Medicines in a deal worth up to $600 million. AZ…
Sino Biopharmaceutical to acquire LaNova Medicines for up to ~$950.9M; LaNova's AstraZeneca LM-305 and Merck LM-299 licenses remain intact.
Source summaries from our enrichment pipeline; follow links for originals.
All 10 sources with sentiment breakdown →
AstraZeneca received an exclusive global license to research, develop and commercialize LM-305, a preclinical GPRC5D-targeting ADC. LaNova received up to $55M in upfront/near-term payments plus up to $545M in development/commercial milestones, with tiered royalties on global net sales. Following the license, AstraZeneca renamed the asset AZD0305 and advanced it from preclinical into an AstraZeneca-sponsored modular Phase I/II dose-escalation study in relapsed/refractory multiple myeloma (NCT06106945; study start December 2023), with early dose-escalation data presented at ASH 2024 — validating the deal thesis of in-licensing a preclinical GPRC5D ADC for clinical advancement. (LaNova's own earlier LM-305 trial, NCT05647512, was withdrawn in November 2023 with no enrollment, superseded by AstraZeneca's program.) LaNova Medicines is separately being acquired by Sino Biopharmaceutical (announced July 2025, up to ~$950.9M); the AstraZeneca LM-305 license remains intact.
36K US cases/yr · $40.0B Global multiple myeloma therapeutic market forecast (2030) · 600 Total AZ-LaNova LM-305 deal size (USD MM upfront + milestones)
Multiple myeloma is the second most common hematologic malignancy in the US, with approximately 35,780 new cases and 12,540 deaths projected in 2024 (SEER/ACS). Despite a dramatic evolution in frontline care over the past decade (triplets and quadruplets built on daratumumab plus proteasome inhibitors and IMiDs, followed by lenalidomide maintenance), essentially all patients eventually relapse. Patients who have exhausted anti-CD38, PI and IMiD classes ("triple-class refractory") carry median overall survival under 12 months in historical series. BCMA-directed therapy (CAR-T and bispecifics) has transformed later-line outcomes since 2020, but resistance and BCMA antigen loss are emerging. GPRC5D (G protein-coupled receptor class C group 5 member D) is selectively expressed on malignant plasma cells with limited normal-tissue expression, making it the leading second-wave myeloma target. The global multiple myeloma therapeutic market was approximately $24B in 2023 and is forecast to exceed $40B by 2030 (EvaluatePharma), with ADCs and T-cell engagers capturing share in later lines.
Multiple myeloma has become pharma's most target-dense oncology indication, with more than a dozen active mechanisms across five generations of therapy. Anti-CD38: Darzalex and Darzalex Faspro (daratumumab, Johnson & Johnson, $9.7B 2023) anchor frontline, with Sarclisa (isatuximab, Sanofi) as a second entrant. IMiDs: Revlimid (lenalidomide, Bristol Myers Squibb, now generic) and Pomalyst (pomalidomide). Proteasome inhibitors: Velcade (bortezomib), Kyprolis (carfilzomib, Amgen), and Ninlaro (ixazomib, Takeda). BCMA CAR-T: Abecma (ide-cel, BMS/2seventy bio) and Carvykti (cilta-cel, Legend Biotech/Johnson & Johnson). BCMA bispecific T-cell engagers: Tecvayli (teclistamab, J&J) and Elrexfio (elranatamab, Pfizer). GPRC5D agents: Talvey (talquetamab, J&J, approved August 2023 as the first GPRC5D bispecific and a direct comparator for LM-305), forimtamig and RG6234 (Roche GPRC5D x CD3 bispecifics), and a growing GPRC5D ADC cohort including LM-305 (AZ/LaNova ADC), CC-95266 (BMS GPRC5D CAR-T), ABBV-383 (AbbVie BCMA bispecific with GPRC5D cross-reactivity cohort), and HPN217 (Harpoon GPRC5D TriTAC). Pfizer's Elrexfio and J&J's Talvey bracket the bispecific opportunity; ADCs like LM-305 offer a parallel modality with potentially lower CRS burden, outpatient administration and an orthogonal resistance profile to T-cell engagers.
AstraZeneca renamed in-licensed LM-305 to AZD0305 and opened a modular Phase I/II dose-escalation study (NCT06106945) in relapsed/refractory multiple myeloma; early data presented at ASH 2024.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| AstraZeneca PLC / LaNova Medicines Ltd. (this deal) | 2023 | $600M | — |
| AstraZeneca PLC / Daiichi Sankyo Company, Limited | 2019 | $6.9B | 100 |
| AstraZeneca PLC / KuDOS Pharmaceuticals Limited | 2005 | $210M | 98 |
| AstraZeneca PLC / Alexion Pharmaceuticals Inc. | 2020 | $39.0B | 86 |
| AstraZeneca PLC / Acerta Pharma | 2015 | $4.0B | 86 |
| AstraZeneca PLC / Amgen Inc. | 2020 | $2.3B | 84 |
| AstraZeneca PLC / MedImmune Inc. | 2007 | $15.6B | 82 |
← Browse all deals · How we score deals
More: 2023 deals · AstraZeneca PLC deals · Hematology deals